- Home
- GWH vs NRXS Comparison
GWH vs NRXS Comparison
Compare GWH & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GWH
- NRXS
- Stock Information
- Founded
- GWH 2011
- NRXS 2011
- Country
- GWH United States
- NRXS United States
- Employees
- GWH N/A
- NRXS N/A
- Industry
- GWH Industrial Machinery/Components
- NRXS
- Sector
- GWH Miscellaneous
- NRXS
- Exchange
- GWH Nasdaq
- NRXS Nasdaq
- Market Cap
- GWH 25.3M
- NRXS 25.0M
- IPO Year
- GWH N/A
- NRXS 2023
- Fundamental
- Price
- GWH $1.57
- NRXS $2.61
- Analyst Decision
- GWH Hold
- NRXS Strong Buy
- Analyst Count
- GWH 4
- NRXS 1
- Target Price
- GWH $2.67
- NRXS $7.00
- AVG Volume (30 Days)
- GWH 155.0K
- NRXS 36.1K
- Earning Date
- GWH 11-12-2025
- NRXS 11-11-2025
- Dividend Yield
- GWH N/A
- NRXS N/A
- EPS Growth
- GWH N/A
- NRXS N/A
- EPS
- GWH N/A
- NRXS N/A
- Revenue
- GWH $6,166,000.00
- NRXS $3,217,531.00
- Revenue This Year
- GWH $131.04
- NRXS $62.14
- Revenue Next Year
- GWH $76.74
- NRXS $131.87
- P/E Ratio
- GWH N/A
- NRXS N/A
- Revenue Growth
- GWH N/A
- NRXS 41.93
- 52 Week Low
- GWH $0.76
- NRXS $1.33
- 52 Week High
- GWH $10.12
- NRXS $6.20
- Technical
- Relative Strength Index (RSI)
- GWH 53.02
- NRXS 58.39
- Support Level
- GWH $1.36
- NRXS $2.31
- Resistance Level
- GWH $1.75
- NRXS $2.65
- Average True Range (ATR)
- GWH 0.13
- NRXS 0.11
- MACD
- GWH 0.03
- NRXS 0.01
- Stochastic Oscillator
- GWH 66.04
- NRXS 79.73
About GWH ESS Tech Inc.
ESS Tech Inc is a long-duration energy storage company specializing in iron flow battery technology. The company design and produce long-duration batteries predominantly using earth-abundant materials.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).